What is Zacks Research’s Estimate for BMRN Q2 Earnings?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Zacks Research increased their Q2 2026 EPS estimates for BioMarin Pharmaceutical in a research report issued to clients and investors on Wednesday, March 12th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $1.00 for the quarter, up from their prior estimate of $0.86. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2027 earnings at $4.78 EPS.

A number of other equities analysts have also recently issued reports on the stock. Scotiabank raised their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, February 20th. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price objective on the stock in a report on Monday, February 24th. Wedbush restated an “outperform” rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Bank of America raised their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Finally, Citigroup raised their target price on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $94.00.

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock opened at $69.44 on Friday. BioMarin Pharmaceutical has a 52-week low of $60.63 and a 52-week high of $94.85. The stock has a market cap of $13.25 billion, a PE ratio of 31.56, a PEG ratio of 0.61 and a beta of 0.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The firm’s 50 day moving average price is $66.22 and its two-hundred day moving average price is $68.80.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million for the quarter, compared to analysts’ expectations of $711.05 million.

Institutional Trading of BioMarin Pharmaceutical

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in BioMarin Pharmaceutical by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 19,372,185 shares of the biotechnology company’s stock valued at $1,273,334,000 after buying an additional 93,531 shares in the last quarter. Primecap Management Co. CA boosted its stake in BioMarin Pharmaceutical by 0.4% in the third quarter. Primecap Management Co. CA now owns 18,867,435 shares of the biotechnology company’s stock valued at $1,326,192,000 after buying an additional 77,350 shares in the last quarter. Dodge & Cox boosted its stake in BioMarin Pharmaceutical by 6.1% in the fourth quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company’s stock valued at $969,270,000 after buying an additional 847,917 shares in the last quarter. Capital Research Global Investors boosted its stake in shares of BioMarin Pharmaceutical by 23.8% during the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company’s stock valued at $853,944,000 after purchasing an additional 2,496,817 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $234,645,000. 98.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,344 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the sale, the chief accounting officer now directly owns 13,105 shares of the company’s stock, valued at $896,119.90. This trade represents a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.85% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.